

Freedom of Information request 015735 – Breast cancer

1/7/21

I am researching the incidence and treatment of breast cancer. I would greatly appreciate if you could answer the following two questions.

Q1. How many patients have you treated (using surgery, radiotherapy or any systemic anti-cancer therapy) in the last three months for:

- Breast cancer (any stage) - 202 patients
- Early breast cancer (both early-stage and locally advanced, inclusive of stages I-IIIc)
- Metastatic breast cancer (stage IV)
- Unable to split by staging information

Q2. How many patients have been treated for breast cancer (any stage) in the past 3 months with the following systemic anti-cancer therapies:

- Abemaciclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole) - 3
- Abemaciclib + Fulvestrant - 14
- Anthracycline (e.g. doxorubicin or epirubicin) as a single agent - 0
- Atezolizumab + Nab-paclitaxel/Paclitaxel - 0
- Capecitabine as a single agent - 14
- Carboplatin or Cisplatin as a single agent - 6
- Eribulin as a single agent or in combination - 7
- Everolimus + Exemestane - 4
- Fluorouracil - 15
- Fulvestrant as a single agent - 0
- Lapatinib - 0
- Neratinib - 14
- Olaparib - 0
- Palbociclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole) - 31
- Palbociclib + Fulvestrant - 12
- Pertuzumab + Trastuzumab + Docetaxel - 14
- Platinum (e.g. carboplatin or cisplatin) as a single agent - 6
- Ribociclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole) - 0
- Ribociclib + Fulvestrant - 0
- Talazoparib - 0
- Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent - 33
- Trastuzumab as a single agent or in combination - 86
- Trastuzumab emtansine - 6

Please note:- The Chemocare prescribing system was only deployed about 2 years ago. Data has now slowly started to build within the system so the Trust is now able to run limited reports. Not all chemotherapy is dispensed via the system and not all regimens can be sorted by disease.